Physician profile
Robert C Greer
NPI 1053319533
$3,950.50
in general payments reported to CMS, 2019-2025
24 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $752 · 2021: $810 · 2022: $459 · 2023: $295 · 2024: $534 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,433.65 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $322.17 | 2021-2025 | |
| Pfizer INC. | $261.73 | 2020-2025 | |
| Lilly USA, LLC | $234.46 | 2022-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $204.51 | 2020-2024 | Trelegy Ellipta |
| Stryker Corporation | $169.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $166.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.77 | 2019-2022 | |
| Novo Nordisk INC | $157.87 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bausch Health US, LLC | $132.94 | 2020-2023 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.50 | 2020-2022 | |
| Allergan, INC. | $111.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $105.85 | 2019-2020 | |
| Exact Sciences Corporation | $83.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.69 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $49.88 | 2021 | |
| Endo Pharmaceuticals INC. | $38.04 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $28.92 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $27.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $20.76 | 2024 | Capvaxive |
| Abbott Laboratories | $18.96 | 2019 | |
| Esperion Therapeutics, INC. | $17.01 | 2020 | |
| Inspire Medical Systems, INC. | $15.89 | 2025 | Inspire |
| Orexo US, INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.